High-flow nasal cannula (HFNC) therapy reduces the effort of breathing in patients with bronchiolitis, but the mechanisms are not understood. Theorized mechanisms include dead space washout and positive end-expiratory pressure (PEEP) application. What are the mechanisms of action of HFNC therapy in patients with bronchiolitis? Prospective, single-center study of children 3 years of age or younger with bronchiolitis from January 2020 through March 2021. Flow was titrated between 0.5 and 2 L/kg/min. Electrical impedance tomography measured end-expiratory lung impedance (EELZ) change as an end-expiratory lung volume (EELV) change surrogate and change in tidal impedance difference (ΔZ) as a tidal volume (VT) surrogate. A subset showed manometry measuring esophageal pressure change (ΔPes; transpulmonary pressure surrogate) and pressure rate product (PRP; effort of breathing metric). We hypothesized that EELV and VT would not change and that effort would reduce via respiratory rate (not ΔPes). Measurements were reported as the difference from 0.5 L/kg/min. We studied 22 patients in total, 10 with esophageal manometry. Median EELZ increased by 0.36 arbitrary unit (AU), 2.42 AU, and 4.8 AU at 1 L/kg/min, 1.5 L/kg/min, and 2 L/kg/min (P = .01, 2 L/kg/min vs 0.5 L/kg/min), which corresponded to a median increase in EELV of 1.8 mL/kg between 0.5 and 2 L/kg/min. Seven patients showed an increase in EELZ of > 5 AU, 12 showed no change in EELZ (± 5 AU), and three showed a decrease in EELZ of > 5 AU. ΔZ (ie, VT) did not change from 0.5 L/kg/min to 2 L/kg/min (median change, 0.29 AU; P = .48). Median PRP decreased by 78 cm H2O/min from 0.5 L/kg/min to 2 L/kg/min (P = .02), with all patients demonstrating a reduction in PRP, with a nonsignificant change in ΔPes (P = .68). Increasing HFNC in children with bronchiolitis reduces the effort of breathing, but no consistent increase occurs in end-expiratory lung volume and no significant change occurs in VT or transpulmonary pressure. This suggests that PEEP application is not the primary mechanism of action of HFNC in children with bronchiolitis.
Background . Foreign body aspiration (FBA) in children has a high morbidity, and early diagnosis is the key for preventing acute and chronic respiratory complications. To diagnose FBA, commonly used imaging modalities have limited negative predictive value, and rigid bronchoscopy remains as the gold standard. We present a case where the diagnosis of FBA was made in a novel way with electrical impedance tomography (EIT). Case Presentation . A 19‐month‐old previously healthy boy was admitted with a clinical diagnosis of respiratory failure secondary to bronchiolitis. Chest X‐ray showed bilateral lung hyperinflation. He enrolled in a research study which used EIT to measure the effects of high flow nasal cannula (HFNC) on minute ventilation in children with bronchiolitis. On initiation, the patient had near‐normal right lung ventilation (98%) and near‐absent left lung ventilation (2%). We discontinued the study and alerted the medical team that we suspected FBA. Further imaging (lateral decubitus films and lung ultrasounds) was also obtained, but was not diagnostic. Rigid bronchoscopy was performed and showed a peanut occluding the left mainstem bronchus (LMB). The peanut was removed followed by complete resolution of the patient’s symptoms. Conclusions . We believe this is the first reported case of FBA diagnosed via EIT. EIT has been shown to be a useful but underutilized technology for diagnosing respiratory disease. While FBA remains a relatively common cause of morbidity and mortality in children less than age four, early diagnosis remains difficult and requires vigilance. This case illustrates the challenges of relying on chest films and ultrasound to assist with diagnosis and suggests that EIT in combination with a thorough history and physical exam can be used to confirm the presence of FBA.
Background: Routine chest X-rays (CXR) are not recommended by the American Academy of Pediatrics in bronchiolitis, yet remain a mainstay in diagnostics. We aimed to understand the impact of obtaining CXRs in patients with critical bronchiolitis, assessing intensive care unit length of stay (ICU-LOS) and intensive care unit level of respiratory support (ICU-LRS). Methods/Design: This single-center retrospective cohort study assessed children less than three years of age admitted to the PICU, pediatric step-down ICU, and pediatric cardiac ICU. Two groups were used for analysis: patients with CXR and no-CXR. The primary outcome was the difference in ICU-LOS and ICU-LRS between the groups. The critical bronchiolitis score (CBS) was used to calculate a predicted ICU-LOS and ICU-LRS. The secondary outcome was the difference between actual and predicted ICU-LOS and ICU-LRS, comparing the groups. Results: Of the 107 patients included, 65 patients (61%) received a CXR. Patients who received a CXR had significantly longer ICU-LOS (p = 0.01) and ICU-LRS (p = 0.02), despite no difference in predicted illness severity (ICU-LOS, p = 0.4; ICU-LRS, p = 0.3). The difference between actual and predicted ICU-LOS was greater in the no-CXR group (–1.4 days) compared to the CXR group (–0.8 days; p = 0.04). A similar trend was observed in ICU-LRS (–0.1 vs. –0.6 days; p = 0.1), though not statistically significant. Conclusions: Routine CXRs are common in critically ill bronchiolitis patients and may be associated with longer ICU-LOS and ICU-LRS, despite similar illness severity.
Objective: The role of bronchodilators in bronchiolitis remains unclear, yet they are commonly used. We evaluated their impact in children based on family history of atopy and viral etiology (RSV and rhinovirus). Methods: This was a single-center, retrospective study of children ≤ 2 years admitted to the PICU, step-down ICU, or cardiothoracic ICU who required high-flow nasal cannula, non-invasive ventilation, or invasive ventilation. Patients were categorized by bronchodilator use and stratified by family history of atopy. Primary outcomes were ICU and hospital length of stay (LOS) and length of respiratory support (LRS). The Critical Bronchiolitis Score (CBS) was used to adjust for illness severity by calculating predicted outcomes and comparing them with the observed values. Secondary analysis evaluated outcomes based on family history of atopy and RSV/ rhinovirus positivity. Results: Of 105 included patients, 56 (53.3%) received bronchodilators. The no-bronchodilator group had shorter ICU-LOS (1.7 vs. 2.5 days; p = 0.0005) and hospital LOS (2.1 vs. 3.4 days; p = 0.0038) compared to the bronchodilator group. Predicted ICU outcomes did not differ between groups. Secondary analyses suggested differences in ICU-LOS (p = 0.007) and hospital LOS (p = 0.02) based on family history of atopy. In rhinovirus-positive patients, both ICU and hospital LOS were shorter without bronchodilators, while no differences were observed in RSV-positive patients. Conclusions: Bronchodilators in critical bronchiolitis were associated with longer inpatient LOS, despite similar predicted illness severity. Neither a family history of atopy nor rhinovirus/RSV positivity affected bronchodilator outcomes. Future prospective research is needed to identify targeted subgroups of patients who may benefit from this therapy.
Background: Routine chest X-rays (CXR) are not recommended by the American Academy of Pediatrics in bronchiolitis, yet remain a mainstay in diagnostics. We aimed to understand the impact of obtaining CXRs in patients with critical bronchiolitis, assessing intensive care unit length of stay (ICU-LOS) and intensive care unit level of respiratory support (ICU-LRS). Methods/Design: This single-center retrospective cohort study assessed children less than three years of age admitted to the PICU, pediatric step-down ICU, and pediatric cardiac ICU. Two groups were used for analysis: patients with CXR and no-CXR. The primary outcome was the difference in ICU-LOS and ICU-LRS between the groups. The critical bronchiolitis score (CBS) was used to calculate a predicted ICU-LOS and ICU-LRS. The secondary outcome was the difference between actual and predicted ICU-LOS and ICU-LRS, comparing the groups. Results: Of the 107 patients included, 65 patients (61%) received a CXR. Patients who received a CXR had significantly longer ICU-LOS (p = 0.01) and ICU-LRS (p = 0.02), despite no difference in predicted illness severity (ICU-LOS, p = 0.4; ICU-LRS, p = 0.3). The difference between actual and predicted ICU-LOS was greater in the no-CXR group (–1.4 days) compared to the CXR group (–0.8 days; p = 0.04). A similar trend was observed in ICU-LRS (–0.1 vs. –0.6 days; p = 0.1), though not statistically significant. Conclusion: Routine CXRs are common in critically ill bronchiolitis patients and may be associated with longer ICU-LOS and ICU-LRS, despite similar illness severity.